Analyst Price Targets — COGT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 1:55 pm | — | Robert W. Baird | $35.00 | $38.29 | TheFly | Cogent Biosciences price target raised to $35 from $34 at Baird |
| February 18, 2026 11:43 am | — | Piper Sandler | $52.00 | $37.62 | TheFly | Cogent Biosciences price target raised to $52 from $39 at Piper Sandler |
| January 7, 2026 5:41 am | Michael Yee | UBS | $60.00 | $34.78 | StreetInsider | UBS Starts Cogent (COGT) at Buy |
| January 6, 2026 11:09 am | — | H.C. Wainwright | $52.00 | $34.26 | TheFly | Cogent Biosciences price target raised to $52 from $50 at H.C. Wainwright |
| December 8, 2025 4:03 pm | — | Jefferies | $48.00 | $39.97 | TheFly | Cogent Biosciences price target raised to $48 from $45 at Jefferies |
| November 11, 2025 9:27 am | Chris Raymond | Raymond James | $60.00 | $32.46 | StreetInsider | Cogent (COGT) PT Raised to $60 at Raymond James, 'remains our Analyst Current Favorite' |
| November 10, 2025 4:01 pm | — | Stifel Nicolaus | $40.00 | $34.97 | TheFly | Cogent upgraded to Buy at Stifel after 'overwhelmingly positive' GIST data |
| November 10, 2025 3:19 pm | David Nierengarten | Wedbush | $38.00 | $34.76 | TheFly | Wedbush upgrades Cogent to Outperform after better-than-expected trial results |
| October 15, 2025 8:13 pm | — | Stifel Nicolaus | $16.00 | $16.58 | TheFly | Cogent Biosciences initiated with a Hold at Stifel |
| September 2, 2025 8:31 pm | — | Raymond James | $30.00 | $12.00 | TheFly | Cogent Biosciences initiated with a Strong Buy at Raymond James |
Latest News for COGT
WALTHAM, Mass. and BOULDER, Colo., Feb. 28, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced additional clinical results from the pivotal SUMMIT trial with bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the American Academy of Allergy Asthma & Immunology…
Cogent Biosciences, Inc. (NASDAQ: COGT - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have issued a buy rating and three have
Rock Springs Capital Management sold 159,278 shares of Cogent Biosciences in the fourth quarter; the estimated trade size was $4.48 million based on quarterly average prices. Meanwhile, the quarter-end stake value rose by $15.68 million, reflecting both trading and price change effects.
First Turn Management acquired 824,283 shares of Cogent Biosciences in the fourth quarter. The quarter-end value for the new stake rose by $29.28 million, reflecting both trading activity and price movement.
SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026 PEAK NDA initiated for bezuclastinib in patients with 2L GIST under Real-Time Oncology Review (RTOR) and Breakthrough Therapy Designation (BTD); completion of NDA on track for April 2026 Six abstracts from SUMMIT trial of bezuclastinib in patients with…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for COGT.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.